GSK to acquire potential best-in-class T cell-engager (TCE) for multiple myeloma from Chimagen Biosc

GSK to acquire potential best-in-class T cell-engager (TCE) for multiple myeloma from Chimagen Biosciences

GSK announced it has entered an agreement to acquire a potential best-in-class trispecific T cell-engager from Chimagen Biosciences.